本帖最后由 老马 于 2012-1-13 21:20 编辑 % ?5 [0 ?) _5 Y0 d% ~
& E* H$ w% I2 s, t. |/ v
爱必妥和阿瓦斯丁的比较
9 o3 V& x( [. K+ k, A* E
, E Z9 f6 f1 d; M s4 Dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 J/ T: T* j( F' Q
7 L- Q" `) Z$ |& @
7 D1 |6 `( @; Z/ \& D- uhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 ]4 n2 R5 f1 J) l8 r& n! V
==================================================1 ?" H3 Q( E# V8 u7 h+ e1 o1 W4 Z4 D
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 m+ N3 v4 c7 P
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% M2 g$ G0 {* AResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.7 o" ^& t% V1 o0 U: ?
|